Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamidronate added to routine treatment for childhood Legg-Calvé-Perthes disease
IRCT20230526058299N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pamidronate in Legg-Calvé-Perthes disease (LCPD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Disease grade, Response to treatment and 2 more. Started Jun 2023; status: completed.
02
Drugs
pamidronate
03
Conditions
Legg-Calvé-Perthes disease (LCPD)
Beyond the preview
Go deeper on IRCT20230526058299N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230526058299N1.